Review
======

The current clinical spectrum of anti-phospholipid syndrome
===========================================================

Formal clinical classification criteria
---------------------------------------

The revised classification criteria for anti-phospholipid syndrome (APS), commonly used as a diagnostic tools for the syndrome, include a history of venous or arterial thrombosis and/or of pregnancy morbidity in the presence of persistent anti-phospholipid antibody (aPL) positivity (Table [1](#T1){ref-type="table"}) \[[@B1]\]. The most common vascular manifestations are deep venous thrombosis of lower limbs, pulmonary embolism and cerebral ischemic attack; early and late miscarriages are the major features of obstetric APS \[[@B1],[@B2]\]. In the catastrophic variant of APS, multiple small-vessel thrombotic events occur at different sites, in association with manifestations of the systemic inflammatory response syndrome \[[@B3]\].

###### 

**Revised classification criteria for anti-phospholipid syndrome**\[[@B1]\]

  **Clinical criteria**                                                     
  ------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
   Vascular thrombosis                                                     One or more episodes of arterial, venous or small vessel thrombosis in any tissue or organ (confirmed by objective validated criteria (imaging study or histopathology))
   Pregnancy complications                                                 One or more unexplained deaths of a morphologically normal fetus ≥10th gestational week
                                                                           One or more premature births (≤34th gestational week) of a morphologically normal neonate because of eclampsia, severe pre-eclampsia or placental insufficiency
                                                                           Three or more unexplained consecutive spontaneous abortions ≤9th gestational week (maternal anatomic and hormonal abnormalities and chromosomal abnormalities excluded)
  **Laboratory criteria**                                                   
   Lupus anticoagulant present in plasma                                   Detected according to the guidelines of the International Society of Thrombosis and Haemostasis (Scientific subcommittee on lupus anticoagulant/phospholipid-dependent antibodies)
   IgG and/or IgM anti-cardiolipin antibodies in serum of plasma           At medium/high titer (≥40 GPL or MPL or ≥99th percentile) measured by standard ELISA
   IgG and/or IgM anti-β~2~ glycoprotein I antibodies in serum or plasma   Titer ≥99th percentile measured by standard ELISA, according to recommended procedures

At least one clinical and one laboratory criterion is mandatory. Autoantibodies have to be confirmed on two or more occasions at least 12 weeks apart. ELISA, enzyme-linked immunosorbent assay; GPL, IgG aPL units; Ig, immunoglobulin; MPL, IgM aPL units.

Clinical manifestations not yet considered as classification criteria
---------------------------------------------------------------------

From the first definition of the disease, the clinical spectrum of APS has notably extended and many other manifestations have been described \[[@B4]\]. Thrombocytopenia, heart valve disease (valve thickening, vegetations and regurgitation), nephropathy, livedo reticularis and skin ulcers are relatively common features of APS but are not included in the classification criteria because of their low specificity (Table [2](#T2){ref-type="table"}) \[[@B5]-[@B9]\].

###### 

Anti-phospholipid syndrome clinical manifestations not yet considered as classification criteria

                                                                                                                           **Frequency**                                                                                                            
  ------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------ ----------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------
   Thrombocytopenia                                                                                                        20-25%                                                 30-40%                                                            Usually mild
  No protective effect on thrombotic risk                                                                                                                                                                                                           
   Heart valve disease                                                                                                     12-33%                                                 40%                                                               Possibly an additional risk for secondary thromboembolism
  Skin                                                                                                                                                                                                                                               
   Livedo reticularis                                                                                                      20-25%                                                 35%                                                               Original association with arterial thrombosis not confirmed in prospective studies
   Ulcers                                                                                                                  33%                                                    7-10%                                                             Pre-tibial area
  Frequently observed in catastrophic APS                                                                                                                                                                                                           
   Superficial thrombophlebitis                                                                                            9%                                                     Reported in aPL-positive patients but their value still debated   
  Kidney                                                                                                                                                                                                                                            
   Renal artery stenosis                                                                                                   26% of aPL + patients with uncontrolled hypertension   Resulting in severe renovascular hypertension, renal infarcts     
   APS nephropathy (renal small artery vasculopathy, involving both arterioles and glomerular capillaries)                 35%^a^                                                 39-67% ^a^                                                        Association with pregnancy complications, extra-renal vascular thrombosis and higher risk of chronic renal failure among SLE patients
  Central nervous system                                                                                                                                                                                                                            
   Migraine/headache                                                                                                       20%                                                    25%                                                               Controversial association with aPLs because of the high prevalence in the general population
   Epilepsy                                                                                                                6-7%                                                   14%                                                               In many but not all cases secondary to ischemic events
  Conflicting data on relationship between aPLs and seizure in SLE                                                                                                                                                                                  
   MS-like disease                                                                                                                                                                                                                                  No definite data regarding prevalence because of the difficult differential diagnosis
   Cognitive impairment                                                                                                    38%                                                    48%                                                               Mostly involving attention and verbal fluency
   Dementia                                                                                                                2.5-56%                                                Resulting from chronic or recurrent ischemic events               
   Ocular manifestations                                                                                                   15-88%                                                 Amaurosis fugax as potential first sign of cerebral ischemia      
  Retinal artery thrombosis vessels (arteries and veins) are relatively frequent and can lead to significant visual loss                                                                                                                            
   Transverse myelopathy                                                                                                   1%                                                     Strong correlation with aPLs in SLE patients                      
   Pulmonary alveolar hemorrhage                                                                                           \<1%                                                   Very poor prognosis                                               

^a^Data from small series, with hypertension or signs suggestive of nephropathy. aPL, anti-phospholipid antibody; APS, anti-phospholipid syndrome; MS, multiple sclerosis; PAPS, primary anti-phospholipid syndrome; SLE, systemic lupus erythematosus.

In addition to thrombo-occlusive events in the cerebral circulation, a wide range of \'non-criteria\' neurological manifestations have been associated with aPL, even though in some cases such association is still controversial. Examples include untreatable headache and migraine, epilepsy, chorea, ocular manifestations such as amaurosis fugax and retinal vessel thrombosis \[[@B10],[@B11]\]. A clinical syndrome and/or magnetic resonance imaging resembling multiple sclerosis has also been described in APS, raising the issue of a correct differential diagnosis \[[@B10]\].

Persistent aPL positivity has been related to cognitive impairment in systemic lupus erythematosus (SLE) patients, even if recent studies in very large SLE cohorts have not confirmed such an association \[[@B11]\]. Although scant, studies in primary APS have reported a high predominance of cognitive deficits involving attention and verbal fluency \[[@B12],[@B13]\]. In addition, several authors reported the occurrence of chronic or recurrent ischemic events affecting small or large cerebral vessels and leading to multi-infarct dementia \[[@B1]\].

Further manifestations affecting different organs or tissues have been described in APS patients. However, their association with aPL is still a matter of research mainly because of the anecdotal nature of the reports or the presence of other underlying disorders (diffuse alveolar hemorrhage, myocardial dysfunction, transverse myelopathy, Guillain-Barré syndrome and multiple mononeuropathy, sensorineural hearing loss or vertigo due to middle ear involvement, splinter hemorrhages and anetoderma \[[@B1]\]).

Diagnostic laboratory tools
===========================

Classification laboratory assays
--------------------------------

Laboratory criteria for formal APS classification currently include three aPL assays: one based on coagulation tests to reveal the presence of lupus anticoagulant (LA) and two solid phase assays to detect IgG/IgM antibodies targeting cardiolipin (CL)/beta~2~ glycoprotein I (β~2~GPI) complexes or β~2~GPI alone (Table [1](#T1){ref-type="table"}). Persistent medium/high positivity (12 weeks apart) of at least one of these tests is mandatory \[[@B1]\].

Risk stratification
-------------------

According to the revised classification criteria, APS patients should be divided into four categories: category I includes patients with more than one positive test in any combination, while patients with a single positive test should be classified in category II (IIA if LA-positive, IIb if positive for antibodies against CL (aCLs), IIc if positive for anti-β~2~GPI antibodies) \[[@B1]\]. Triple positivity, defined by the presence of LA and medium/high titers of aCL and anti-β~2~GPI antibodies (above the 99th percentile), is the most predictive profile for clinical manifestations and recurrences despite conventional treatment \[[@B14],[@B15]\].

There is growing evidence that patients in category II have a lesser risk to develop APS manifestations. LA was reported to be the most predictive test. LA can be mediated by both anti-β~2~GPI and anti-prothrombin (aPT) antibodies \[[@B16]\]. However, β~2~GPI-dependent LA was found to be a stronger risk factor for thrombosis and miscarriages than aPT-dependent LA \[[@B17],[@B18]\]. aCL positivity alone is not associated with an increased risk of thrombosis or pregnancy loss \[[@B16],[@B17],[@B19]\]. Data on anti-β~2~GPI antibodies are more controversial, maybe because the assay is less standardized \[[@B17]\]. Accordingly, Otomo and colleagues \[[@B20]\] have recently validated a scoring system to quantify the thrombotic or obstetric risk depending on aPL profiles.

Clinical events are more robustly associated with aPLs of the IgG isotype, an isolated positivity for aCLs or anti-β~2~GPI antibodies of the IgM isotype being rarely detected in APS cohorts. Patients carrying both aCL/anti-β~2~GPI antibody isotypes display a higher risk of developing clinical events \[[@B21]\]. Some investigators have recently proposed that aCLs and anti-β~2~GPI IgA antibodies be included in the APS laboratory criteria. However, this is not supported by available data: the detection of a single IgA aPL positivity is more commonly associated with non-criteria manifestations, while IgA testing has not been shown to increase the diagnostic accuracy for APS \[[@B22]\]. Interestingly, this is not consistent with *in vivo* findings, which are supportive for a pathogenic role of IgA β~2~GPI-dependent aPLs in mediating thrombus formation \[[@B23]\].

While it is well accepted that aPLs confer a prothrombotic susceptibility when at high titers, controversies have recently arisen about the clinical meaning of low-titer aPLs in pregnancy morbidity. A few studies have reported that women with persistent low-titer aPL positivity display an obstetric outcome comparable to the general population \[[@B17]\]. On the other hand, a recent study showed that low-titer aCL and anti-β~2~GPI antibody positivity (between the 95th and 99th percentiles) accurately identifies women with aPL-related pregnancy complications \[[@B24]\].

Risk stratification for thrombotic events should also take into account the presence of traditional cardiovascular factors such as systemic inflammatory conditions (infectious or autoimmune), inherited thrombophilia, arterial hypertension, cigarette smoking and dyslipidemia \[[@B1]\]. Risk-factors for pregnancy failure include low complement levels, decreased platelet counts and a previous history of thrombosis and pregnancy failure \[[@B15]\].

Non-classification laboratory assays
====================================

Additional laboratory tests to detect aPLs have been reported: the most important \'non-classification\' tests still deal with the two major phospholipid (PL)-binding proteins thought to represent the true antigenic targets for aPL: β~2~GPI and prothrombin (PT) \[[@B16]\]. However, other autoantigens have been described that are a matter of debate and research (Table [3](#T3){ref-type="table"}).

###### 

Future research requirements for the most promising non-classification laboratory assays

  **Test**                                                                 **Assay**                                           **Future research needs**
  ------------------------------------------------------------------------ --------------------------------------------------- ---------------------------------------------------
  Anti-DI antibodies                                                       ELISA                                               Analytical and post-analytical standardization
  CIA                                                                      Retrospective and prospective clinical validation   
  Anti-PS/PT antibodies                                                    ELISA                                               Analytical and post-analytical standardization
  Retrospective confirmatory studies and prospective clinical validation                                                       
  Anti-PE antibodies                                                       ELISA                                               Analytical and post-analytical standardization
  Retrospective confirmatory studies and prospective clinical validation                                                       
  Annexin A5 resistance assay                                              Two-step coagulation assay                          Analytical and post-analytical standardization
                                                                                                                               Retrospective and prospective clinical validation

CIA, chemiluminescence immunoassay; DI, domain I; ELISA, enzyme-linked immunosorbent assay; PE, phosphatidylethanolamine; PS/PT, phosphatidylserine-prothrombin.

Anti-prothrombin antibodies
---------------------------

To be antigenically recognized, human PT has to be either coated on activated plates or exposed to immobilized anionic phosphatidylserine (PS) via calcium ions. ELISAs to detect antibodies against the PS/PT complex (aPS/PT antibodies) identify a partially different autoantibody population from the assay using PT as the only antigen \[[@B25]\]. A contentious issue concerns the potential cross-reactivity between aPS/PT and anti-β~2~GPI antibodies; however, human anti-β~2~GPI monoclonals or affinity-purified anti-β~2~GPI polyclonal IgG antibodies obtained from a serum reacting with both β~2~GPI and PS/PT have been shown to react towards β~2~GPI only \[[@B26]\].

*In vitro* experimental findings suggest that aPTs exert thrombogenic effects interfering with fluid phase components of coagulation and activating endothelial cells (ECs). Evidence from animal models is rather weak, however, mainly because of the lack of cross-reactivity of human aPTs with animal PT \[[@B25]\].

The wide variability in epitope specificities and detection methods drives a disparity across available studies about the prevalence and clinical significance of aPTs. The prevalence of antibodies targeting PT depends also on selection of study populations: when considering solely individuals with LA, the positivity rate increases up to 85% and 88% for aPTs and aPS/PTs, respectively \[[@B25]\]. Similarly, the clinical significance of aPTs in both primary and secondary APS is still a matter of debate. Some studies showed that aPTs are an independent risk factor for either venous or arterial thrombosis, while others have failed to demonstrate such an association. On the other hand, most of the studies addressing the clinical significance of aPS/PTs have highlighted a significant association with aPL-associated manifestations, in particular venous thrombosis. Consistently, a systematic review did not find any correlation between aPTs and clinical events, while a more recent one found that aPS/PTs are a stronger risk factor for arterial and venous thrombosis than aPTs \[[@B27]\]. Much more controversial remains the association of aPTs and aPL-related pregnancy morbidity (Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}).

###### 

Studies addressing prevalence and clinical association of aPT antibodies

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Reference**                                  **Study population**                 **N**                           **Prevalence of anti-PT**                    **Clinical association**
  ---------------------------------------------- ------------------------------------ ------------------------------- -------------------------------------------- ----------------------------------------------------------------------------------
  Fleck *et al*. \[[@B28]\]                      LA positive subjects                 42                              74%                                          NI

  Pengo *et al*. \[[@B29]\]                      APS patients                         22                              50%                                          No association with thrombosis

  Horback *et al*. \[[@B30]\]                    SLE patients                         175                             38%                                          Association with thrombosis\
                                                                                                                                                                   (IgG and IgM)

  Puurunen *et al*. \[[@B31]\]                   SLE patients                         139                             34%                                          Association with DVT

  Swadzba *et al*. \[[@B32]\]                    SLE patients with thrombotic event   127                             28%                                          No association with thrombosis (IgG and IgM)

  31                                                                                                                                                               

  Galli *et al*. \[[@B33]\]                      aPL-positive subjects                59                              58%                                          No association with thrombosis

  IgG 35.6%                                                                                                                                                        

  IgM 37.3%                                                                                                                                                        

  Bertolaccini *et al*. \[[@B34]\]               SLE patients                         207                             28%                                          No association with APS clinical manifestations

  Forastiero *et al*. \[[@B35]\]                 APS patients                         97                              25%                                          Association with thrombosis

  aPL-negative patients with thrombotic events   83                                                                                                                

  Munoz-Rodriguez *et al*. \[[@B36]\]            APS patients                         70                              57%                                          Association with arterial thrombosis (IgG only)

  SLE patients                                   107                                  40%                                                                          

  Atsumi *et al*. \[[@B37]\]                     Patients with autoimmune diseases    265                             IgG: PAPS 15%; SLE APS 42%; SLE no APS 20%   No association with APS

  IgM: PAPS 5%; SLE APS 4%; SLE No APS 6%                                                                                                                          

  Galli *et al*. \[[@B38]\]                      LA-positive patients                 72                              85%                                          No association with APS

  Nojima *et al*. \[[@B39]\]                     SLE patients                         124                             IgG 52.4%                                    Association with venous thromboembolism (only aPT IgG + LA)

  IgM 21%                                                                                                                                                          

  Nojima *et al*. \[[@B40]\]                     SLE patients                         168                             56%                                          Association with arterial thrombosis

  Simmelink *et al*. \[[@B41]\]                  LA-positive patients                 46                              30%                                          Association with thrombosis

  LA-positive patients with SLE                  29                                   LA-positive subjects: 70%                                                    

  LA-negative patients                           38                                                                                                                

  LA-negative patients with SLE                  36                                                                                                                

  Salcido-Ochoa *et al*. \[[@B42]\]              APS patients                         38                              IgG 26%, IgM 11%                             Association with thrombosis

  SLE patients                                   466                                  IgG 20%, IgM 33%                                                             

  Von Landenberg *et al*. \[[@B43]\]             APS patients                         170                             IgG 61.7%                                    Association with pregnancy loss (IgG only)

  (57% PAPS; 43% SAPS)                                                                IgM 57.6%                                                                    

  IgA 7%                                                                                                                                                           

  Musial *et al*. \[[@B44]\]                     APS patients                         22                              IgG 45.4%, IgM 50%                           No association with thrombosis

  SLE patients                                   160                                  IgG 18.1%, IgM 18.7%                                                         

  SLE-like patients                              22                                   IgG 31.8%, IgM 27.3%                                                         

  Ishikura *et al*. \[[@B45]\]                   SLE patients                         22                              18.2%                                        Association with venous thrombosis

  Patients with                                                                                                                                                    

  DVT/PTE                                        48                                   IgG 29%, IgM 8.3%                                                            

  Stroke                                         30                                   IgG 16.7%, IgM 6.7%                                                          

  Koskenmies *et al*. \[[@B46]\]                 SLE patients                         292                             20%                                          Association with arterial thrombosis

  Bertolaccini *et al*. \[[@B47]\]               SLE patients                         212                             31%                                          Association with venous/arterial thrombosis (IgG only)

  IgG-only 24.5%                                                                                                                                                   

  IgM-only 5%                                                                                                                                                      

  Bizzarro *et al*. \[[@B48]\]                   aCL-positive APS patients            25                              60%                                          Association with thrombosis (IgG only)

  SLE-APS patients                               23                                   45%                                                                          

  SLE-no APS patients                            66                                                                                                                

  Forastiero *et al*. \[[@B49]\]                 aPL-positive subjects (LA/aCL)       194                             46%                                          Association with thrombosis (IgG only)

  IgG 36%                                                                                                                                                          

  IgM 23%                                                                                                                                                          

  Gould *et al*. \[[@B50]\]                      SLE patients                         100                             20%                                          No association with thrombosis

  Tsutumi *et al*. \[[@B51]\]                    SLE patients                         139                             25%                                          Association with thrombosis

  Nojima *et al*. \[[@B52]\]                     SLE patients                         175                             54.3%                                        No association with thrombosis

  Bizzaro *et al*. \[[@B53]\]                    SLE patients                         101                             IgG 13.9%                                    Association with thrombosis (IgG only)

  IgM 9%                                                                                                                                                           

  IgG + IgM 3%                                                                                                                                                     

  Sailer *et al*. \[[@B54]\]                     LA-positive subjects                 79                                                                           No association with thrombosis

  With thrombosis                                50                                   72% (assay I), 50% (assay II)                                                

  Without thrombosis                             29                                   66% (assay I), 41% (assay II)                                                

  Bardin *et al*. \[[@B55]\]                     APS patients                         62                              42%                                          NI

  Jakowski *et al*. \[[@B56]\]                   APS patients                         58                              22%                                          No association with pregnancy loss

  Women with recurrent pregnancy loss            66                                   12%                                                                          

  Szodoray *et al*. \[[@B57]\]                   SLE patients                         85                              IgG 18%, IgM 0                               NI

  Pengo *et al*. \[[@B58]\]                      LA-positive subjects                 231                             IgG 26%                                      No association with APS clinical events

  IgM 27%                                                                                                                                                          

  Marozio *et al*. \[[@B59]\]                    Obstetric APS patients               187                             29.4%                                        Association with severe pre-eclampsia, HELLP syndrome, intra-uterine fetal death

  IgG 25.8%                                                                                                                                                        

  IgM 1.8%                                                                                                                                                         

  IgG + IgM: 1.8%                                                                                                                                                  

  Hoxha *et al*. \[[@B60]\]                      PAPS patients                        158                             IgG 23.5%, IgM 4.9%                          Association with thrombosis and obstetric manifestations (IgG only)

  Thrombotic APS                                 56                                   IgG 10.7%, IgM 1.8%                                                          

  Obstetric APS                                  102                                                                                                               

  Sater *et al*. \[[@B61]\]                      Women with recurrent miscarriages    277                             IgM 12%                                      No association with pregnancy loss
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

aCL, anti-cardiolipin antibody; aPL, anti-phospholipid antibody; APS, anti-phospholipid syndrome; aPT, anti-prothrombin antibody; DVT, deep vein thrombosis; HELLP, hemolysis, elevated liver enzymes and low platelet count; Ig, immunoglobulin; LA, lupus anticoagulant; NI, not investigated; PAPS, primary anti-phospholipid syndrome; PTE, pulmonary thromboembolism; SAPS, secondary anti-phospholipid syndrome; SLE, systemic lupus erythematosus.

###### 

Studies addressing prevalence and clinical association of aPS/PT antibodies

  **Reference**                               **Studied population**              **N**                         **Prevalence of anti-PS/PT**                 **Clinical association**
  ------------------------------------------- ----------------------------------- ----------------------------- -------------------------------------------- ------------------------------------------------------------
  Galli *et al*. \[[@B33]\]                   aPL-positive subjects               59                            90%                                          No association with thrombosis
  IgG 75%                                                                                                                                                    
  IgM 66%                                                                                                                                                    
  Atsumi *et al*. \[[@B37]\]                  Patients with autoimmune diseases   265                           IgG: PAPS 19%; SLE APS 63%; SLE-no APS 13%   Association with APS
  IgM: PAPS 10%; SLE APS 29%; SLE-no APS 4%                                                                                                                  
  Nojima *et al*. \[[@B62]\]                  SLE patients                        126                           38.1%                                        No association with stroke
  Bertolaccini *et al*. \[[@B47]\]            SLE patients                        212                           31%                                          No association with thrombosis
  IgG-only 16%                                                                                                                                               
  IgM-only 6%                                                                                                                                                
  Tsutumi *et al*. \[[@B51]\]                 SLE patients                        139                           21%                                          Association with thrombosis
  Nojima *et al*. \[[@B52]\]                  SLE patients                        175                           43.4%                                        Association with thrombosis
  Bardin *et al*. \[[@B55]\]                  APS patients                        62                            55%                                          NI
  Jakowski \[[@B56]\]                         APS patients                        58                            44%                                          No association with pregnancy loss
  Women with RPL                              66                                  1%                                                                         
  Atsumi *et al*. \[[@B63]\]                  Patients with autoimmune diseases   441                           18.3%                                        Association with APS
  PAPS                                        84                                  39%                                                                        
  SLE-APS                                     68                                  47%                                                                        
  SLE-no APS                                  136                                 10%                                                                        
  Rheumatoid arthritis                        46                                  0                                                                          
  Sjogren syndrome                            36                                  0                                                                          
  Other                                       71                                  4%                                                                         
  Žigon *et al*. \[[@B64]\]                   APS patients                        100                           59%                                          NI
  Vlagea *et al*. \[[@B65]\]                  PAPS patients                       98                            51%, IgG 35.7%, IgM 32.6%                    Association with venous thrombosis and obstetric morbidity
  SAPS patients                               45                                  53.3%, IgG 40%, IgM 31.1%                                                  
  aPL-positive subjects                       57                                  38.6%, IgG 21.1%, IgM 26.3%                                                
  Pregnolato *et al*. \[[@B26]\]              APS patients                        80                            81.3%                                        Association with venous thrombosis (IgG only)

aPL, anti-phospholipid antibody; APS, anti-phospholipid syndrome; aPS, anti-phosphatidylserine antibodies; Ig, immunoglobulin; NI, not investigated; PAPS, primary anti-phospholipid syndrome; PS, phosphatidylserine; PT, prothrombin; RPL, recurrent pregnancy loss; SAPS, secondary anti-phospholipid syndrome; SLE, systemic lupus erythematosus.

aPS/PTs have been proposed as a surrogate test for LA and as an additional serological marker of APS, to be performed with other aPL tests to improve diagnosis. Noteworthy, LA together with aβ~2~GPI and aPS/PT antibodies has recently been identified to display the best diagnostic accuracy for both vascular and obstetric APS among 23 possible combinations of six aPL assays (LA, aCLs, anti-β2GPI antibodies, aPTs, aPS/PTs, and anti-phosphatidylethanolamine antibodies (aPEs)) \[[@B66]\]. However, the bulk of evidence is still not solid enough to recommend routine testing for antibodies targeting PT as shown by a summary of all studies available in the literature (Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}).

New assays for anti-β~2~GPI antibodies: the anti-domain antibodies
------------------------------------------------------------------

β~2~GPI is a relatively large plasma glycoprotein of 70 kDa with good immunogenic properties. Thus, it is not surprising that APS patients can produce antibodies against several epitopes of the molecule as demonstrated using different experimental approaches. Although the epitope specificity using linear peptides was not originally reported to be associated with specific clinical manifestations of the syndrome, more recently a close association between anti-domain (D)I reactivity and vascular events has been suggested \[[@B67]\].

The reactivity against DI of β~2~GPI was described for the first time in 2002 but its importance was revealed when a two-step technique was used to characterize β~2~GPI-dependent aPLs \[[@B68]\]. Specifically, β~2~GPI coated on hydrophilic but not hydrophobic microtiter plates displays conformational changes that expose DI to the surface, making it more accessible for autoantibody binding. Anti-β~2~GPI antibodies with DI specificity were found in the majority of APS patients and were significantly associated with LA and vascular thrombosis (mostly venous) \[[@B69]\]. Only in a subsequent multicenter study were they also found to be associated with the obstetric manifestations of the syndrome, although to a lesser extent than with thrombosis \[[@B70]\]. However, some data from the multicenter study are controversial. In fact, no correlation between LA and miscarriages was found, in contrast to several previous publications and the known clinical LA predictive value for miscarriages \[[@B17]\]. High levels of antibodies with comparable specificity and detected by a research ELISA kit have been recently associated with an increased risk for thrombotic events in a prospective cohort of SLE or aPL patients by the same group \[[@B71]\].

Recent studies have demonstrated that patients with multiple positive test results (that is, LA, aCLs and anti-β~2~GPI autoantibodies particularly of the IgG isotype) display a much higher risk for developing clinical complications \[[@B17]\]. In line with the hypothesis that anti-DI IgG may represent a more predictive aPL profile, these patients tend to have a higher prevalence and higher titers of anti-β~2~GPI-DI antibodies \[[@B72],[@B73]\].

Anti-β~2~GPI-DI IgG antibodies have been found as the most prevalent antibodies not only in primary APS with thrombosis but also in primary APS with pure obstetric disease. Comparable positivity rates were detectable in patients with SLE or undifferentiated connective tissue diseases, while antibodies against DIV or DV were less frequent in the same populations \[[@B73]\]. aPL positive asymptomatic carriers display a less polarized profile, suggesting that anti-DI antibodies may cluster in patients with systemic autoimmune diseases \[[@B73]\]. Interestingly, the two techniques for anti-DI antibodies used in the study (that is, standard ELISA and chemiluminescence immunoassay (CIA)) have been reported to display the same specificity but different sensitivities \[[@B74]\].

Additional epidemiological studies apparently support the diagnostic/predictive value of anti-DI antibodies. IgG reacting with β~2~GPI in sera from aPL-positive asymptomatic carriers, individuals with leprosy or children with atopic dermatitis have been shown to preferentially recognize epitopes on DIV or DV \[[@B68]\]. Recent studies have suggested that the ratio between anti-β~2~GPI-DI and anti-β~2~GPI-DIV/V IgG antibody reactivities can provide important information to discriminate between anti-β~2~GPI antibodies linked to an autoimmune disease such as APS and antibodies occurring in association with other pathologies \[[@B73]\]. If confirmed in larger studies, this finding would suggest the use of tests for antibodies against the different domains to discriminate between predictive versus non predictive anti-β~2~GPI antibodies.

In any case, it is difficult to draw definite conclusions on the diagnostic and prognostic value of anti-DI antibodies at this stage. The high prevalence of anti-DI IgG antibodies in patients with medium-high titers of aPLs and multiple positivities in the formal diagnostic tests supports the role of DI as the immunodominant epitope of β~2~GPI. However, a small but consistent proportion of full-blown APS patients have autoantibodies reacting with different epitopes, suggesting that the assay for the whole molecule cannot be substituted yet \[[@B73]\]. The discrepancies in the clinical associations can be related to the different methodologies used. Besides the two-step assay, three ELISA studies and a CIA employing different DI molecules or peptides have been reported \[[@B74],[@B75]\]. Although preliminary data seem to indicate that the solid phase assays by two different ELISAs or CIA are comparable, there is no information on the comparison with the two-step assay and the additional ELISAs. Confirmatory studies using multi-center setups and larger prospective patient cohorts are needed to confirm the data.

The fact that the anti-DI antibodies are directed against the immunodominant epitope of β~2~GPI is supported also by pathogenic studies in animal models. Passive infusion of a synthetic antigenic target peptide DI was shown to protect naïve mice from the thrombogenic effects of human polyclonal aPL IgG fractions \[[@B76]\]. Although the inhibition of thrombus formation as well as expression of adhesion molecule on aortic ECs and tissue factor expression on macrophages were not complete, this finding was thought to represent a proof of concept of the pathogenic role of anti-DI antibodies \[[@B76]\]. More recently, a human monoclonal IgG, specifically reacting with DI, was shown to induce clotting and fetal loss in naïve mice, offering the first direct demonstration of the pathogenic effect of anti-DI antibodies \[[@B77]\]. Interestingly, the anti-DI monoclonal induced clotting via complement activation and only after the concomitant administration of small amounts of lipopolysaccharide. This finding is in line with previous results obtained using polyclonal IgG anti-β~2~GPI fractions from APS patients and further supports the potential pathogenic role of anti-DI antibodies.

The main epitope of DI has been suggested to be a cryptic and conformation-dependent structure involving different residues located in the proximity of the junction between DI and DII. Fine epitope mapping using short synthetic peptide fragments and mutation experiments have demonstrated that the main epitope on β~2~GPI-DI is located around amino acid 40 of the molecule with R39-R43 representing the key constituent of the discontinuous epitope \[[@B68]\]. DI of β~2~GPI is usually hidden, being linked with DII in the circular form of the molecule, the most abundant variant in the circulation. After interaction with anionic PL monolayers or when bound to endotoxin, β~2~GPI is opened and DI can be presented to the afferent limb of the immune system \[[@B69]\]. In other words, it could be speculated that, unlike the other domains, which can induce tolerance at high antigen concentrations, DI does not. So, even a small amount of DI presented to the immune system can break the tolerance and easily induce specific antibodies.

Antibodies against phosphatidylethanolamine
-------------------------------------------

Phosphatidylethanolamine (PE) is a zwitterionic PL, mainly located in the inner leaflets of biological membranes. Subpopulations of aPE bind to high molecular weight kininogen, leading to the formation of antibody-PE-kininogen trimolecular complexes that enhance thrombin-induced platelet aggregation. PE promotes thrombosis by activating factor X and PT, and works as an anticoagulant potentiating activated protein C activity. The finding that PE in the hexagonal phase inhibits the prolongation of clotting time led to the hypothesis that aPEs might be responsible for the LA phenomenon, despite a lack of a significant association between the two assays \[[@B78]\]. A clear *in vivo* demonstration of the pathogenic role of aPEs in mediating vascular and obstetric events is lacking.

Antibodies against PE have been described in up to 43% of APS patients, a higher positivity rate compared to healthy controls \[[@B78]\]. In particular, aPE prevalence among women experiencing recurrent pregnancy loss (RPL) has been reported to range between 23 and 31.7% \[[@B79]\]. Overall, available evidence on the clinical role of aPEs is inconsistent and comes from a limited number of studies, being flawed by the small sample size and poor ELISA standardization \[[@B78]\]. Therefore, aPE testing is currently not recommended, with these autoantibodies not yielding increased accuracy in diagnosing APS. Nevertheless, some authors have proposed aPEs as serological markers of seronegative APS, a debated nosological entity characterized by a clinical picture highly suggestive of APS despite persistent aPL undetectability. In patients with otherwise unexplained thrombotic events, the prevalence of aPEs was 18% when detected by ELISA, rising to 30.5% when tested using thin-layer immunostaining \[[@B78],[@B80]\]. Further, in a multicenter study on 270 thrombotic patients, 63% of 40 aPE-positive subjects had no additional aPL laboratory tests \[[@B78]\].

Antibodies against anionic phospholipids other than cardiolipin
---------------------------------------------------------------

The diagnostic and prognostic roles of several autoantibodies targeting negatively charged PLs other than CL have been evaluated, though not extensively, in the setting of APS.

PS, phosphatidylinositol and phosphatidic acid, three anionic PLs found in the inner and outer membranes of most cells, are among the best-characterized antigens. Noteworthy, in the 1980s aCLs were shown to broadly cross-react with antibodies targeting both PS and phosphatidylinositol. The cross-reactivity was mostly supported by the recognition of the complex of β~2~GPI with the different anionic PLs. In fact, being a cationic molecule, β~2~GPI binds efficiently to negatively charged PLs. Hence, the largest part of the cross-reactivity is actually due to the same family of autoantibodies, namely those reacting with β~2~GPI \[[@B81]\]. As a whole, testing for antibodies against PS (aPSs), phosphatidylinositol and phosphatidic acid does not improve the likelihood of diagnosing APS compared with criteria tests, being therefore not recommended in international guidelines \[[@B1]\].

Nevertheless, aPSs were reported to be promising, with a particular relevance in obstetric APS. In a study on 872 women with RPL, aPSs were the only detectable aPLs in 3.6% of subjects \[[@B82]\]. However, contradictory data have recently emerged: in one study, aPSs were not related to RPL, while other authors identified IgG but not IgM aPSs as associated with RPL. On the other hand, there is no evidence for an association between aPSs and vascular events \[[@B82]\].

Two murine monoclonal antibodies targeting PS (one reacting with both CL and PS and one with PS only) inhibited the development and invasion by trophoblasts, decreased human chorionic gonadotropin levels and retarded syncytiotrophoblast formation. Unfortunately there is no information whether they recognized β~2~GPI or not \[[@B82]\]. Conversely, the β~2~GPI dependence was shown to be important in another study in which active immunization with β~2~GPI-dependent polyclonal human IgG but not IgM aPSs induced fetal resorption via the production of murine β~2~GPI-dependent IgG aPSs \[[@B83]\]. Discrepancies across available studies justify why APS criteria do not include aPS assays among laboratory tools.

A novel ELISA kit detecting antibodies against a mixture of negatively charged PLs comprising PS, phosphatidic acid and β~2~GPI (APhL) has been recently introduced to the market. This commercial immunoassay has been suggested to overcome the issue of the low specificity of aCLs, which are frequently detected in infectious conditions such as chronic hepatitis C, leprosy, syphilis, and parvovirus B19 infection among others. Furthermore, the APhL assay displays higher positive and negative predictive values for APS diagnosis compared to two commercially available aCL assays \[[@B84]\]. In a cohort of 158 SLE patients, multivariate analysis revealed an association between APhL and thrombotic events, particularly arterial \[[@B85]\].

Antibodies against vimentin
---------------------------

Proteomic analysis of endothelial-surface membrane proteins in sera from patients with so-called seronegative APS led to the identification of vimentin as a strong autoantigen. Vimentin, a ubiquitous cytoskeleton intermediate filament protein, has been shown to bind CL *in vitro*. In one cohort of patients, antibodies against vimentin/CL were described in 55% of seronegative APS and 92% of full-blown APS patients \[[@B82]\]. However, antibodies against vimentin/CL have also been reported in aPL-negative SLE and rheumatoid arthritis subjects without any clinical manifestation suggestive of APS, thus weakening the specificity of such a diagnostic marker \[[@B82]\].

Annexins: annexin A5 resistance assay and autoantibodies against annexin A5 and annexin A2
------------------------------------------------------------------------------------------

Annexins are a family of ubiquitous calcium-dependent PL-binding proteins. Annexin (Ann)A5 is a potent anticoagulant protein mainly found in trophoblasts and vascular ECs. Upon binding to anionic PLs, it undergoes oligomerization to form a protective shield against coagulation enzymes. β~2~GPI-dependent aPLs have been shown to interfere with the protective binding of AnnA5 to the endothelium, hence leading to thrombosis. A novel two-stage coagulation assay to establish the AnnA5 resistance has been developed; patients with coagulation time lower than the reference are considered AnnA5-resistant \[[@B81],[@B82]\]. Data from five studies revealed that 52% of APS patients were AnnA5-resistant, in comparison with 2 to 5% of controls and seronegative subjects \[[@B81]\]. Resistance to AnnA5 anticoagulant activity was found to inversely correlate with titers of IgG antibodies targeting DI in both thrombotic and obstetric APS \[[@B81]\]. Future studies will assess whether this functional test may allow the identification of specific subsets of pathogenic anti-β~2~GPI antibodies. The clinical significance of serum autoantibodies against AnnA5 has also been investigated: in one study, no association was reported between these autoantibodies and vascular events, while inconsistencies emerged across different studies in obstetric APS \[[@B81],[@B82]\].

AnnA2, a cofactor for plasmin generation and cell-surface localization of fibrinolytic activity, has been identified as a receptor mediating β~2~GPI binding to ECs. Autoantibodies against AnnA2 have been demonstrated to exert a prothrombotic activity by activating ECs, inducing tissue factor expression and blocking tissue plasminogen activator-induced plasminogen activation *in vitro*. A high prevalence of AnnA2 antibodies has been described in patients with APS, but also in some other autoimmune conditions, thus lowering the specificity of this biomarker \[[@B86]\].

More than just autoantibodies
=============================

The presence of aPLs, even if persistent over time, does not explain the full spectrum of APS. For example, a comparable aPL profile can be associated with vascular but not obstetric manifestations and, in some cases, women with APS and previous miscarriages do not display any vascular events \[[@B1],[@B4]\]. In other words, autoantibodies with the same autoantigen specificity and titers have been associated with different clinical pictures and found to support diverse pathogenic mechanisms in experimental models \[[@B16]\].

β~2~GPI-dependent aPL IgG fractions were reported to affect signaling pathways in monocytes and trophoblast cell lines in different ways depending on whether they were obtained from patients with vascular thrombosis or from women with aPL-related miscarriages only \[[@B87]\]. Hence, the eventual clinical picture has been linked to autoantibodies with the same antigen specificity but different biological effects: induction of a pro-thrombotic and inflammatory phenotype in monocytes by β~2~GPI-dependent IgG antibodies from vascular APS patients and inhibition of trophoblast development by β~2~GPI-dependent IgG antibodies from obstetric APS patients \[[@B87]\].

It is still unclear whether these different effects can be related to diverse IgG epitope specificity. The use of these IgG fractions in animal models of aPL-induced thrombosis or fetal loss could further support such an elegant hypothesis *in vivo*.

Vascular and the obstetric APS have been suggested to represent two different variants of the syndrome \[[@B88]\]. The most striking difference is represented by the need of a second hit for triggering thrombosis in naive animals passively infused with human aPLs, while this is not apparently required in models of fetal loss. In fact, the infusion of aPL IgG fractions in pregnant naive mice can itself induce fetal loss and growth retardation. It has been recently demonstrated that β~2~GPI displays a peculiar tissue distribution in resting naive animals, being detectable only at the level of uterine endothelium but not in other vascularized tissues \[[@B89]\]. So the presence of anti-β~2~GPI antibodies can affect pregnancy outcome in resting animals but it does not trigger any vascular thrombosis. Animal pre-treatment with small amounts of lipopolysaccharide may induce the presence of β~2~GPI in vascularized tissues and only then can aPLs react with the target, activate the complement cascade and induce thrombosis \[[@B89]\]. Accordingly, it has been suggested that the modulation of β~2~GPI tissue distribution by inflammatory stimuli may represent an additional variable able to affect the ability of the antibodies to induce the vascular manifestations of the syndrome \[[@B16],[@B89]\].

Post-transcriptional modifications of β~2~GPI, such as oxidation, have been shown to affect autoantibody binding \[[@B90]\]. For example, autoimmune anti-β~2~GPI IgG antibodies react more strongly with plates coated with oxidized β~2~GPI than antibodies obtained after active immunization in naive animals. Moreover, plasma levels of oxidized β~2~GPI have been found to be increased in sera of APS patients. Altogether, these findings suggest that increased levels of post-transcriptionally modified β~2~GPI and the higher antibody reactivity against the modified molecule may affect the biological consequences of aPL binding \[[@B90]\].

In addition, aPLs can be detected in so-called asymptomatic positive carriers who display the persistent presence of medium to high levels of antibodies but in whom no clinical events can be documented. It has been suggested that the second hit cannot take place in these subjects or that their antibodies display different antigen specificity. In line with the last hypothesis, the epitope specificity of the β~2~GPI-dependent IgG antibodies in these subjects was found to be more frequently directed against DIV or DV than against DI as in full-blown APS sera \[[@B68],[@B74]\]. Since the DI epitope is available for the autoantibodies on the open molecule only (for example, when bound to anionic PL monolayers), it has been hypothesized that only these antibodies may be pathogenic. Figure [1](#F1){ref-type="fig"} presents a schematic view of the above discussed pathogenic mechanisms.

![**Schematic views of anti-phospholipid syndrome pathogenic mechanisms. (a)** Vascular anti-phospholipid syndrome (APS). Anti-phospholipid antibodies (aPLs) may target different cell types and soluble coagulations factors. Pathogenic aPLs are beta~2~ glycoprotein I (β~2~GPI)-dependent and activate complement after an inflammatory stimulus (second hit). Additional variables may affect aPL pathogenicity, such as the ability of antibodies to modulate different cell signaling and to display diverse epitope specificity and reactivity with modified β~2~GPI. **(b)** Obstetric APS. β~2~GPI-dependent aPLs may target trophoblast and decidual cells. β~2~GPI can be present at the uterine level even in non-pregnant animals and it binds to trophoblast cells (syncytiotrophoblasts). A second hit is not apparently required, and female hormones or the pregnancy itself may be the equivalent of the second hit described for the vascular manifestations. As in vascular APS, the ability of antibodies to modulate different cell signaling and to display diverse epitope specificity and reactivity with modified β~2~GPI may be additional variables that can affect aPL pathogenicity. APC, activated protein C; C?S, Protein C/S; FII, Factor II; FIXa, Factor IXa, FVIIa, Factor VIIa; FXa, Factor Xa; PT, prothrombin; TF, tissue factor; tPA, tissue plasminogen factor.](ar4549-1){#F1}

Conclusion
==========

The clinical spectrum of APS is more polymorphic than it was thought in the past, making the syndrome much closer to a systemic autoimmune disease. Additional laboratory tests have been proposed in order to improve diagnostic and predictive power, but promising findings have been reported only for anti-PS/PT and anti-DI antibodies.

aPLs play a major pathogenic role in inducing clinical manifestations; however, there is growing evidence that inflammatory stimuli are pivotal for triggering thrombosis, while tissue distribution of the major antigenic target (β~2~GPI) as well as its post-transcriptional modifications or the fine epitope specificity of anti-β~2~GPI antibodies may influence the type of clinical events or even their occurrence.
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